These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 19228428)

  • 21. Benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on lung function and exacerbations of COPD: a post-hoc analysis of the KRONOS study by blood eosinophil level and exacerbation history.
    Muro S; Kawayama T; Sugiura H; Seki M; Duncan EA; Bowen K; Marshall J; Megally A; Patel M
    Respir Res; 2024 Aug; 25(1):297. PubMed ID: 39103901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial.
    Hardy J; Baggott C; Fingleton J; Reddel HK; Hancox RJ; Harwood M; Corin A; Sparks J; Hall D; Sabbagh D; Mane S; Vohlidkova A; Martindale J; Williams M; Shirtcliffe P; Holliday M; Weatherall M; Beasley R;
    Lancet; 2019 Sep; 394(10202):919-928. PubMed ID: 31451207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD.
    Kuna P; Jenkins M; O'Brien CD; Fahy WA
    Respir Med; 2012 Apr; 106(4):531-9. PubMed ID: 22197578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Budesonide/formoterol via Turbuhaler® versus formoterol via Turbuhaler® in patients with moderate to severe chronic obstructive pulmonary disease: phase III multinational study results.
    Fukuchi Y; Samoro R; Fassakhov R; Taniguchi H; Ekelund J; Carlsson LG; Ichinose M
    Respirology; 2013 Jul; 18(5):866-73. PubMed ID: 23551359
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study.
    Rabe KF; Atienza T; Magyar P; Larsson P; Jorup C; Lalloo UG
    Lancet; 2006 Aug; 368(9537):744-53. PubMed ID: 16935685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD.
    Cazzola M; Santus P; Di Marco F; Boveri B; Castagna F; Carlucci P; Matera MG; Centanni S
    Respir Med; 2003 May; 97(5):453-7. PubMed ID: 12735659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial.
    Calverley PM; Kuna P; Monsó E; Costantini M; Petruzzelli S; Sergio F; Varoli G; Papi A; Brusasco V
    Respir Med; 2010 Dec; 104(12):1858-68. PubMed ID: 20965712
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Formoterol: a review of its use in chronic obstructive pulmonary disease.
    Cheer SM; Scott LJ
    Am J Respir Med; 2002; 1(4):285-300. PubMed ID: 14720051
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease.
    Calverley PM; Boonsawat W; Cseke Z; Zhong N; Peterson S; Olsson H
    Eur Respir J; 2003 Dec; 22(6):912-9. PubMed ID: 14680078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial.
    Noonan M; Rosenwasser LJ; Martin P; O'Brien CD; O'Dowd L
    Drugs; 2006; 66(17):2235-54. PubMed ID: 17137405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma.
    FitzGerald JM; Boulet LP; Follows RM
    Clin Ther; 2005 Apr; 27(4):393-406. PubMed ID: 15922813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A score to predict short-term risk of COPD exacerbations (SCOPEX).
    Make BJ; Eriksson G; Calverley PM; Jenkins CR; Postma DS; Peterson S; Östlund O; Anzueto A
    Int J Chron Obstruct Pulmon Dis; 2015; 10():201-9. PubMed ID: 25670896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler in Chinese Patients with COPD: A Subgroup Analysis of KRONOS.
    Wang C; Yang T; Kang J; Chen R; Zhao L; He H; Assam PN; Su R; Bourne E; Ballal S; DeAngelis K; Dorinsky P
    Adv Ther; 2020 Apr; 37(4):1591-1607. PubMed ID: 32152869
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial.
    Dalby C; Polanowski T; Larsson T; Borgström L; Edsbäcker S; Harrison TW
    Respir Res; 2009 Oct; 10(1):104. PubMed ID: 19878590
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial.
    Rabe KF; Pizzichini E; Ställberg B; Romero S; Balanzat AM; Atienza T; Lier PA; Jorup C
    Chest; 2006 Feb; 129(2):246-256. PubMed ID: 16478838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with traditional fixed dosing: a five-month multicentre Canadian study.
    FitzGerald JM; Sears MR; Boulet LP; Becker AB; McIvor AR; Ernst P; Smiljanic-Georgijev NM; Lee JS;
    Can Respir J; 2003; 10(8):427-34. PubMed ID: 14679407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish healthcare perspectives.
    Mittmann N; Hernandez P; Mellström C; Brannman L; Welte T
    Pharmacoeconomics; 2011 May; 29(5):403-14. PubMed ID: 21504240
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
    Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
    Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fixed or adjustable maintenance-dose budesonide/formoterol compared with fixed maintenance-dose salmeterol/fluticasone propionate in asthma patients aged >or=16 years: post hoc analysis of a randomized, double-blind/open-label extension, parallel-group study.
    Aalbers R
    Clin Drug Investig; 2010; 30(7):439-51. PubMed ID: 20528000
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fluticasone/formoterol combination therapy versus budesonide/formoterol for the treatment of asthma: a randomized, controlled, non-inferiority trial of efficacy and safety.
    Bodzenta-Lukaszyk A; Buhl R; Balint B; Lomax M; Spooner K; Dissanayake S
    J Asthma; 2012 Dec; 49(10):1060-70. PubMed ID: 23102189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.